This month, Hoosier Cancer Research Network features our member institution Froedtert & the Medical College of Wisconsin in Milwaukee, Wis., and Deepak Kilari, MD, a medical oncologist with specialization in genitourinary cancers.

Research Interests and Expertise:

Dr. Kilari’s research interests and clinical practice both focus on the treatment of genitourinary malignancies with an emphasis on the elderly population. He leads several investigator-initiated trials and is sponsor-investigator of the current phase II HCRN study, GU18-343, where researchers are evaluating neoadjuvant cabozantinib and atezolizumab in muscle-invasive bladder cancer. Dr. Kilari is also a member of HCRN’s Genitourinary Clinical Trial Working Group.

Additionally, Dr. Kilari’s research seeks to better understand the mechanisms of resistance to current standard therapies in prostate cancer. He is board certified in internal medicine and has presented his research at national meetings and in peer-reviewed journals.

Educational Background:

• Medical School: Andhra Medical College, Visakhapatnam, India
• Residency: Internal Medicine, New York Presbyterian, Brooklyn, NY
• Hematology and Oncology, Fellowship: University of Rochester, NY

Three facts about Dr. Kilari:

• He likes to cook, especially different Indian cuisines.
• He is an avid bicyclist.
• He loves traveling with family and exploring new places.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.